Pediatric diabetes devices and technology

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

Most parents of children starting continuous glucose monitoring soon after their type 1 diabetes diagnosis find virtual initiation to be convenient and effective, shows a small study.

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.

The Omnipod 5 closed-loop, tubeless insulin delivery system has achieved good results in young children with type 1 diabetes over 12 months, with no cases of severe hypoglycemia or diabetic ketoacidosis recorded.

The iLet bionic pancreas closed-loop insulin delivery system provides good glucose control without the need for the user to count carbohydrates, show findings from the pivotal trial.

Hybrid closed-loop therapy significantly improves glycemic control and quality of life relative to continuous subcutaneous insulin infusion or multiple daily insulin injections in children and adolescents with type 1 diabetes, research shows.

Closed-loop control with the Cambridge hybrid system improves time in range in very young children with type 1 diabetes relative to sensor-augmented pump delivery over 16 weeks of use, researchers report.

Impaired hypoglycemia awareness is present in a substantial proportion of children and young people with type 1 diabetes and is associated with an increased risk for severe hypoglycemia, suggests research presented at the virtual 57th EASD Annual Meeting.

The Cambridge closed-loop insulin delivery system significantly improves glycemic control during 6 months of use by children and adolescents compared with standard insulin pump therapy, report the DAN05 investigators.

Use of the Omnipod 5 closed-loop insulin delivery system reduces diabetes distress and improves quality of life, particularly for the carers of children with type 1 diabetes, research shows.

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

Use of continuous glucose monitoring within the first month of diagnosis is associated with an improvement in glycemic control among youth with type 1 diabetes, indicate findings from the 4T study.

A closed-loop system with an artificial intelligence component that rapidly detects when the user is eating a meal may offer a route towards fully closed-loop insulin delivery, shows a small crossover trial in adolescents and young adults.

Use of an insulin pump is not associated with better glycemic control than multiple daily injections among children and adolescents with type 1 diabetes, indicate real-world study results.

The use of continuous glucose monitoring does not increase time in range in young children with type 1 diabetes, but may improve other glycemic indices, researchers report.

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.